![]() |
市场调查报告书
商品编码
1625232
至 2030 年 Beta 伏打电池设备市场预测:按同位素类型、设备配置、应用、最终用户和地区进行的全球分析Betavoltaic Device Market Forecasts to 2030 - Global Analysis By Isotope Type (Tritium (H-3), Nickel-63, Promethium-147 and Other Radioisotopes), Device Configuration, Application, End User and By Geography |
||||||
根据 Stratistics MRC 的数据,2024 年全球 beta voltaic 装置市场规模为 2.047 亿美元,预计预测期内复合年增长率为 12.8%,到 2030 年将达到 4.217 亿美元。
贝塔伏特装置,也称为贝塔伏特电池或电池,利用放射性同位素发射的贝塔粒子来发电。这些设备的工作原理是β崩坏,其中高能量电子与半导体材料相互作用产生电流。 Beta 伏特装置以其长达数十年的长使用寿命而闻名,用于需要可靠、免维护电源的应用,例如医疗植入、远端感测器和太空技术。其紧凑的设计和耐用性使其成为恶劣或难以进入的环境的理想选择。
根据《应用物理学杂誌》报导,贝塔伏特装置已证明能够在超过 733K(460°C;860°F)的高温环境中运作。
可长时间供电
Betavolta 设备提供长寿命电源,其使用寿命通常长达数十年。如此长的使用寿命非常适合无法定期维护或更换电池的偏远地区或恶劣环境中的应用,例如太空任务、水下感测器和医疗植入。无需充电即可提供持续电力的能力使其在可靠性和耐用性非常重要的航太和医疗保健等多个领域具有吸引力。
开发成本高
高开发成本是贝塔伏特元件市场的主要限制因素。这些成本是由复杂的製造流程以及安全处理放射性同位素所需的专门材料和技术造成的。此外,严格的安全和环境合规监管要求也增加了经济负担。这些因素可能会限制新参与企业的市场进入,减缓技术创新的步伐,并阻碍贝塔伏特设备的广泛采用。
技术进步
科技的进步为太阳能电池市场带来了巨大的机会。材料科学和半导体技术的创新正在提高设备的效率和功率。这些进步正在提高贝塔伏特设备在更广泛应用中的实用性,包括物联网设备和先进的医疗植入。随着改善能源转换过程和降低生产成本的研究不断取得进展,市场有望扩展到需要可靠、长期电力解决方案的新领域。
放射性同位素的供应有限
放射性同位素的有限供应对贝塔伏特设备市场构成了威胁。氚等放射性同位素对于这些设备至关重要,但供应量并不丰富,这可能会导致供应链限制和成本增加。这种稀缺性可能会促使製造商寻求替代材料和技术,从而将投资从β太阳能电池解决方案上转移出去。
由于供应链中断和原材料短缺,COVID-19 大流行扰乱了 β 电压元件市场。封锁措施减缓了生产活动,并导致产品开发和部署的延迟。然而,随着经济復苏和监管放鬆,随着关键应用中对可靠电源解决方案的需求增加,市场预计将復苏。
氚 (H-3) 领域预计将在预测期内成为最大的领域
由于氚 (H-3) 领域作为 β 伏打设备发电的 β 辐射源的有效性,预计在预测期内将占据最大的市场占有率。氚的半衰期长,因此可以长时间提供稳定的电力而无需维护。由于与其他同位素相比,它们很容易获得且相对便宜,因此它们是需要耐用电源的应用的首选,例如医疗植入和远端感测器。
医疗植入领域预计在预测期内复合年增长率最高。
在预测期内,由于医疗保健领域对持久电源解决方案的需求不断增加,医疗植入产业预计将出现最高的复合年增长率。 Betavolta 设备在为心律调节器等植入植入供电、消除频繁更换电池以及减少手术干预方面具有显着优势。慢性病的盛行率不断上升,需要可靠的能源来源,透过确保设备的连续功能来增强患者护理,从而推动该领域的成长。
由于先进的技术基础设施以及在国防和医疗保健领域的大量投资,预计北美地区将在预测期内占据最大的市场占有率。主要产业参与者的存在和持续的研究倡议进一步推动了市场的成长。该地区专注于开发创新电源解决方案,以满足航太和医疗设备等关键应用对可靠能源来源的需求。
由于快速工业化和对可再生能源技术投资的增加,预计亚太地区在预测期内将实现最高成长率。中国、日本和韩国等国家正在各行业扩大使用紧凑、可靠的电源。该地区对技术进步的承诺支持了 beta-voltaic 设备市场的强劲成长轨迹。
According to Stratistics MRC, the Global Betavoltaic Device Market is accounted for $204.7 million in 2024 and is expected to reach $421.7 million by 2030 growing at a CAGR of 12.8% during the forecast period. A betavoltaic device, also known as a betavoltaic cell or battery, generates electricity using beta particles emitted by radioactive isotopes. These devices operate on the principle of beta decay, where energetic electrons interact with a semiconductor material, creating an electric current. Known for their long operational life, often spanning decades, betavoltaic devices are used in applications requiring reliable, maintenance-free power, such as medical implants, remote sensors, and space technology. Their compact design and durability make them ideal for harsh or inaccessible environments.
According to the Journal of Applied Physics, betavoltaic devices have demonstrated the ability to operate in high-temperature environments exceeding 733 K (460 °C; 860 °F).
Offers long-lasting power supply
Betavoltaic devices provide a long-lasting power supply, often lasting several decades, which is a significant driver for their market. This longevity makes them ideal for applications in remote or harsh environments where regular maintenance or battery replacement is impractical, such as in space missions, underwater sensors, and medical implants. Their ability to deliver continuous power without recharging enhances their appeal across various sectors, including aerospace and healthcare, where reliability and durability are critical.
High development costs
High development costs are a major restraint for the betavoltaic device market. These costs stem from the complex manufacturing processes and the need for specialized materials and technology to safely handle radioactive isotopes. Additionally, stringent regulatory requirements for safety and environmental compliance add to the financial burden. These factors can limit market entry for new players and slow down the pace of innovation, potentially hindering the widespread adoption of betavoltaic devices.
Advancements in technology
Advancements in technology present significant opportunities for the betavoltaic device market. Innovations in materials science and semiconductor technology are enhancing the efficiency and power output of these devices. Such advancements make betavoltaic devices more viable for a broader range of applications, including IoT devices and advanced medical implants. As research continues to improve energy conversion processes and reduce production costs, the market is poised for expansion into new sectors requiring reliable, long-term power solutions.
Limited availability of radioactive isotopes
The limited availability of radioactive isotopes poses a threat to the betavoltaic device market. Isotopes like tritium are crucial for these devices but are not abundantly available, which can lead to supply chain constraints and increased costs. This scarcity may drive manufacturers to seek alternative materials or technologies, potentially diverting investments away from betavoltaic solutions.
The Covid-19 pandemic disrupted the betavoltaic device market due to supply chain interruptions and raw material shortages. Lockdown measures slowed production activities, leading to delays in product development and deployment. However, as economies recover and restrictions ease, the market is expected to rebound with increased demand for reliable power solutions in critical applications.
The tritium (H-3) segment is expected to be the largest during the forecast period
The tritium (H-3) segment is expected to account for the largest market share during the forecast period due to its effectiveness as a beta radiation source for generating electricity in betavoltaic devices. Tritium's long half-life allows these devices to provide consistent power over extended periods without maintenance. Its availability and relatively low cost compared to other isotopes make it a preferred choice for applications requiring durable power sources, such as medical implants and remote sensors.
The medical implants segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the medical implants segment is expected to witness the highest CAGR due to increasing demand for long-lasting power solutions in healthcare. Betavoltaic devices offer significant advantages in powering implants like pacemakers, eliminating frequent battery replacements and reducing surgical interventions. The growing prevalence of chronic diseases necessitates reliable energy sources that enhance patient care by ensuring continuous device functionality, driving growth in this segment.
The North America region is anticipated to account for the largest market share during the forecast period due to its advanced technological infrastructure and significant investments in defense and healthcare sectors. The presence of key industry players and ongoing research initiatives further bolster market growth. The region's focus on developing innovative power solutions aligns with the demand for reliable energy sources in critical applications like aerospace and medical devices.
The Asia Pacific region is anticipated to register the highest growth rate over the forecast period driven by rapid industrialization and increasing investments in renewable energy technologies. Countries like China, Japan, and South Korea are expanding their use of compact and reliable power sources across various industries. The region's commitment to technological advancement supports its robust growth trajectory in the betavoltaic device market.
Key players in the market
Some of the key players in Betavoltaic Device Market include Widetronix, NDB, Inc., City Labs Inc., Qynergy Corporation, II-VI Incorporated, NorthStar Battery Co LLC, Exide Technologies, EaglePicher Technologies LLC, Curtiss-Wright Corporation, General Atomics, Thermo Fisher Scientific, Advent Technologies, Mouser Electronics, BetaBatt Inc., SHV Energy, Tech Etch Inc., H3 Battery LLC and Comsoll Inc.
In November 2024, City Labs has been awarded a Commercialization Readiness Pilot (CRP) from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health. This significant funding will support the advancement of City Labs' innovative betavoltaic battery for leadless pacemakers, employing scalable fabrication techniques to prepare the technology for pre-clinical testing.
In July 2024, City Labs announced that it has been selected by AFWERX for a $1,250,000 Small Business Innovation Research (SBIR) Phase II contract. This award further supports the novel development of an advanced radioisotope-powered ion engine designed for small satellites. Building on the successful proof-of-concept City Labs established in the previously awarded Phase I contract, this Phase II effort aims to address critical propulsion challenges for the U.S. Department of the Air Force and lay the groundwork for producing a fully operational engine in the future that is capable of supporting missions lasting over five years.
In August 2020, NDB, Inc., creator of the first and only universal, self-charging, proprietary nano diamond battery (NDB) that provides up to thousands of years of charge announced completion of two successful Proofs of Concept tests of the NDB battery at Lawrence Livermore National Laboratory and the Cavendish Laboratory at Cambridge University. NDB's battery achieved a breakthrough 40% charge, a significant improvement over commercial diamonds, which have only 15% charge collection efficiency. NDB also announced its first two beta customers, including a leader in nuclear fuel cycle products and services and a leading global aerospace, defense and security manufacturing company.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.